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Abstract Cryptococcal meningitis is a recognized
complication of systemic lupus erythematosus (SLE), with
high mortality rates, particularly in those treated with
immunosuppressive agents. We describe a patient diag-
nosed simultaneously with cryptococcal meningoencepha-
litis and SLE and reviewed four similar cases reported in
the literature. In our case, profound low CD4 lymphocyte
count and low complement levels were observed. The
patient was treated with prednisolone, ﬂuconazole, and
5-ﬂucytosine and evinced good clinical improvement. This
case suggests that intrinsic immunological abnormality
related to SLE predisposed to opportunistic infections.
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Introduction
Despite a signiﬁcant increase in the survival rate of patients
with systemic lupus erythematosus (SLE), infection is a
signiﬁcant cause of morbidity and mortality [1]. The risk
factors of infections include immunosuppressive therapies
and some manifestations of active SLE itself [2–4]. The
central nervous system (CNS) is rare organ system of
infections [3], and cryptococcal meningoencephalitis has
been described as one of life-threatening causes of CNS
infection in patients with SLE [5, 6]. We describe a rare
case of simultaneous presentation of cryptococcal menin-
goencephalitis and SLE. Opportunistic infections can
present concurrently with new-onset SLE.
Case report
A 47-year-old man was admitted with a 2-week history of
fever, headache, generalmalaise, and anorexia. He had been
well until 10 months before admission when he began to
have wrist, knee, and ankle arthritis, which persisted for
4 months and resolved spontaneously. Two weeks prior to
presentation, he noted fever of 37–37.8C in the evenings
and lost 2 kg in weight over those 2 weeks. On physical
examination, his temperature was 37.2C, blood pressure
112/62 mmHg, and pulse 60 bpm. Neither skin rash nor oral
ulcer was noted; his chest was clear, with no murmurs or
rubs. No abdominal tenderness was present, and the liver
and spleen could not be palpated. Arthritis was not
observed, and meningismus was absent. Other neurological
examination was normal. Laboratory values were as fol-
lows: leukocytes 3,000/ll; lymphocytes 249/ll; platelets
205,000/ll; serum immunoglobulin G (IgG) 2,520 mg/dl,
IgA 140 mg/dl, and IgM 60 mg/dl; total functional
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DOI 10.1007/s10165-010-0383-6hemolytic complement (CH50) 14 U/ml (normal 32–47
U/ml); C3 56 mg/dl (normal 65–135 mg/dl); C4 5 mg/dl
(normal 13–35 mg/dl). Liver enzymes, blood urea nitrogen
(BUN), serum creatinine (SCr), serum electrolytes, and
urinalysis were all normal. Serum antinuclear antibodies
were positive at a titer of 1:2,560, with peripheral pattern.
Serum antibodies to double-stranded DNA titer were
markedly elevated at 165 IU/ml (normal\12 IU/ml). SLE
was diagnosed, and Systemic Lupus Erythematosus Disease
Activity Index (SLEDAI) [7] was 5. Low complement,
increased DNA binding, and leukopenia were descriptors.
On hospital day 1, loxoprofen sodium (120 mg daily)
was prescribed for headache and was somewhat effective.
He had been afebrile after admission, but anorexia per-
sisted. On hospital day 8, he complained of neck pain. The
next day, hallucination, apraxia, and agnosia appeared.
Meningismus was noted. Magnetic resonance imaging
(MRI) of the brain with gadolinium contrast showed
interhemispheric and occipital meningeal enhancement
suggesting adjacent meningitis (Fig. 1). Cerebrospinal ﬂuid
(CSF) examination showed 212 white blood cells/ll
(neutrophils 2, lymphocytes 210, unclassiﬁed 29), glucose
60 mg/dl, and protein 146 mg/dl. An India-ink preparation
of the CSF revealed mucinous capsule of cryptococcus as a
translucent halo surrounding budding yeast. A latex-
agglutination test was positive for cryptococcal antigen at a
dilution of 1:2,048, and CFS culture grew Cryptococcus
neoformans. Cryptococcal meningoencephalitis was diag-
nosed based on clinical manifestations, MRI ﬁndings, and
CSF examinations. Human immunodeﬁciency virus (HIV)
serology was negative, but lymphocyte and CD4 lympho-
cyte counts were 200 and 33/ll, respectively. CD4/CD8
was 0.47 (normal 0.69–1.74). He was treated with intra-
venously administered ﬂuconazole (800 mg daily) and 5-
ﬂucytosine orally (8,000 mg daily). Prednisolone (30 mg
daily) was administered concomitantly to treat SLE. On
hospital day 15, headache, neck pain, hallucination,
apraxia, agnosia, and meningismus had disappeared com-
pletely. After 8-weeks, ﬂuconazole IV was changed to oral
administration (400 mg daily). On hospital day 100, CSF
examination showed 89 white blood cells/ll, (neutrophils
1, lymphocytes 88, and unclassiﬁed 1). Cryptococcus was
still positive on India-ink staining. However, CFS culture
did not grow C. neoformans. His lymphocytes, CD4 lym-
phocytes, CH50, C3, and C4 recovered to 1,100/ll, 176/ll,
42 U/ml, 99 mg/dl, and 14 mg/dl, respectively. On hospital
day 106, he was discharged with good clinical improve-
ment. Oral 5-ﬂucytosine was discontinued at that time.
Prednisolone had been tapered to 10 mg daily. He con-
tinued taking ﬂuconazole orally (400 mg daily) as main-
tenance therapy for 12 months. He has remained well for
more than 3 years without relapses.
Discussion
The spectrum of infections reported in patients with SLE
varies. Gram-positive cocci, gram-negative bacilli, Myco-
bacterium tuberculosis, Candida albicans, C. neoformans,
Pneumocystis jirovecii, cytomegalovirus, Epstein–Barr
virus, and herpes virus have all been implicated [2–6, 8].
Use of steroids ever [3] and disease activity [2, 4] are
signiﬁcantly associated with infections. SLEDAI score [7]
of 4 or higher in outpatients and[8 in hospitalized patients
are signiﬁcant predicting factors for infection development
[2, 4]. Death in which infection is the primary cause is
signiﬁcantly associated with the peak corticosteroid dose
received as treatment [9]. The major organ systems of
infections often include skin, genitourinary, and lung [2–4].
CNS infections are rare in patients with SLE. Gladman
et al. [3] reported that CNS infections consisted of four
(2.7%) of 148 infection episodes in 93 patients with SLE.
Clinical manifestations of CNS infections including head-
ache, cognitive disorder, and acute confusional state, and
seizure can mimic manifestations of CNS lupus. CNS
infections should be carefully excluded when a patient with
SLE displays CNS manifestations, even prior to the initi-
ation of immunosuppressive therapies.
Cryptococcal meningoencephalitis had been described
as a rare complication of SLE [5]. However, Hung et al. [6]
reported that cryptococcal meningoencephalitis played the
major role in CNS infections of patients with SLE. They
Fig. 1 Brain magnetic resonance imaging (fast, low-angle inversion
recovery sequences). Postcontrast view showing enhanced interhemi-
spheric and occipital meninges
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a 20-year follow up of 3,165 patients with SLE, and ten
(59%) of 17 patients had been diagnosed with cryptococcal
meningoencephalitis. The average SLEDAI score in these
ten patients was 4.3. Kim et al. [10] reported four cases of
cryptococcus meningoencephalitis during a 15-year follow
up of 1,155 patients with SLE. SLEDAI scores of these
four cases were 8 or higher. The outcome of these patients
with cryptococcal meningoencephalitis was uniformly
poor. Mortality rates were as high as 40–50% despite
antifungal therapy [5, 6]. Headache, fever, diplopia, nau-
sea, and vomiting were symptoms for nonimmunosup-
pressed patients with CNS cryptococcosis at presentation
[11, 12]. Sivalingam et al. [13] reported that normal neu-
rological and CSF examinations did not exclude crypto-
coccal meningoencephalitis in a patient with SLE.
Cryptococcal meningoencephalitis should be considered as
a differential in SLE patients presenting even nonspeciﬁc
symptoms of headaches, fevers, nausea, or vomiting.
Most patients previously reported with cryptococcal
meningoencephalitis had received corticosteroid adminis-
tration when cryptococcal meningoencephalitis was diag-
nosed [5]. To our knowledge, there have been four
previous reports of a patient who developed cryptococcal
meningoencephalitis simultaneously with the diagnosis of
SLE or prior to immunosuppressive therapy (Table 1)
[6, 14–16]. Mok et al. [14] reported that the ﬁrst case of
cryptococcal meningoencephalitis complicating SLE
without immunosuppressive therapy. Their case revealed
normal CD4 lymphocyte count and low complement levels.
The second reported case showed profound hypocomple-
mentemia and lupus nephritis [15]. Hung et al. [6] reported
that one of ten patients had cryptococcus meningoen-
cephalitis simultaneously with initial diagnosis of SLE.
Chen et al. [16] reported 15 cases with invasive fungal
infection in SLE. Their case series included one case
of cryptococcal meningoencephalitis complicating SLE
without prednisolone administration. All cases were
women, and SLEDAI scores in three cases were 4, 7, and
11, respectively (Table 1). Mortality rate was high at 50%.
It is difﬁcult to identify the intrinsic immunological
abnormality as the risk for cryptococcal meningoencepha-
litis development in SLE patients other than immunosup-
pressive therapy. Host resistance to C. neoformans depends
primarily on cell-mediated immunity. CD4 lymphocytes,
cytotoxic lymphocytes, natural killer cells, activated mac-
rophages, and various cytokines including interleukin 12,
granulocyte–macrophage colony-stimulating factor, and
interferon-c are implicated in successful host responses to
C. neoformans [17]. Decreased CD4 lymphocyte count,
natural killer cell activity, and T-cell cytotoxicity are related
to SLE clinical activity [18]. In this case, immunosuppres-
sive agents were not administered at cryptococcal menin-
goencephalitis diagnosis, despite which the patient’s CD4
lymphocyte count and complement levels were low. The
profound, progressive loss of CD4 lymphocyte in HIV
patients correlates with the appearance of cryptococcal
meningoencephalitis, with the highest risk found when CD4
lymphocyte counts fall\100/ll[ 17]. However, CD4 lym-
phocyte count was normal in the ﬁrst case report of a patient
who developed cryptococcal meningoencephalitis simulta-
neously with the diagnosis of SLE (Table 1)[ 14]. Godeau
etal.[8] reported that twoof sixSLE patients hadP. jiroveci
pneumonia prior to corticosteroid administration. Lympho-
cyte count of one of these two patients was low, at 180/ll.
However,theotherpatientwasnotlymphocytopenic.Ecevit
et al. [11] described nine nonimmunosuppressed patients
with CNS cryptococcosis. Pappas et al. [19] reported that 47
of 157 HIV-negative patients had cryptococcus meningo-
encephalitis without underlying conditions. Zonios et al.
[12]reviewed53patientswithcryptococcosisandidiopathic
CD4 lymphocytopenia. Idiopathic CD4 lymphocytopenia is
a syndrome deﬁned by the repeated presence of a CD4
lymphocyte count\300/llo r\20% of total T cells, with no
evidence of HIV infection and no conditionthat might cause
low CD4. Selective defect in lymphocyte responsiveness to
C. neoformans might explain cryptococcus meningoen-
cephalitis in otherwise normalhosts.CD4 lymphocytecount
should be measured in patients with cryptococcus menin-
goencephalitis without underlying conditions. Complement
Table 1 Clinical characteristics of patients with cryptococcal meningoencephalitis at the diagnosis of systemic lupus erythematosus (SLE) or
prior to immunosuppressive therapy
Patient Ref. Age/sex CD4 count (/ll) C3 (mg/dl) C4 (mg/dl) SLEDAI Antifungal therapy Outcome
1[ 14] 48/F Normal 23 9 4
a AMB/5-FC/Flu Survived
2[ 15] 30/F ND 24 3 LN AMB/Flu Survived
3[ 6] 56/F ND ND ND 7 AMB/Flu Died
4[ 16] ND/F ND ND ND 11 ND Died
5 This case 47/M 33 56 5 5 5-FC/Flu Survived
Ref. reference, ND no data was available, LN lupus nephritis, AMB amphotericin B, 5-FC ﬂucytosine, Flu ﬂuconazole, SLEDAI Systemic Lupus
Erythematosus Disease Activity Index
a Calculated based on case description
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123levels in two previous case reports and in our case were low
(Table 1)[ 14, 15]. Complement has been shown to be an
opsonic requirement for in vitro phagocytosis of C. neofor-
mans by rat macrophages [20]. Shapiro et al. [21] reported
the importance of C3 in defense against cryptococcus
infection by demonstrating increased susceptibility for
genetically deﬁcient C3 knockout mice. Low CD4 lym-
phocyte count and/or complement levels might contribute to
thedevelopmentofopportunisticfungalinfectioninpatients
with SLE even prior to immunosuppressive therapy.
The recommended therapy for cryptococcal meningo-
encephalitis in HIV-negative and nontransplant patients
includes induction therapy with amphotericin B deoxy-
cholate (0.7–1.0 mg/kg daily) plus ﬂucytosine (100 mg/kg
daily) for at least 4 weeks, followed by a consolidation
therapy with ﬂuconazole (400–800 mg daily) for 8 weeks
and another 6–12 months of reduced-dose of ﬂuconazole
(200 mg daily) for maintenance therapy [22]. Nussbaum
et al. [23] reported that combination ﬂucytosine and high-
dose ﬂuconazole was an optimal regimen for treating
cryptococcal meningitis in HIV-seropositive patients. In
this case, ﬂuconazole plus ﬂucytosine administration was
successful. If toxic side effects of amphotericin B develop,
ﬂuconazole plus ﬂucytosine regimen might be considered.
Our case represents the ﬁfth case report of a patient
diagnosed with cryptococccal meningoencephalitis con-
current with the diagnosis of SLE. Intrinsic immunological
abnormality of SLE itself can predispose to opportunistic
infections, even in the absence of immunosuppressive
therapies. However, additional case experience is required
to conﬁrm their relationship.
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